JiaYu Chang1, XuQuan Jing1, Ying Hua1,2, KaiXing Geng1,3, RuYue Li1,4, ShuangQing Lu1, Hui Zhu1, Yan Zhang5. 1. Department of Oncology, Shandong Cancer Hospital and Institute Affiliated to Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, China. 2. Tianjin Medical University, Tianjin, 300060, China. 3. Zaozhuang Tumor Hospital, Zaozhuang, 277102, China. 4. Weifang Medical University, Weifang, 261053, China. 5. Department of Oncology, Shandong Cancer Hospital and Institute Affiliated to Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, China. zhangyan0681@163.com.
Abstract
PURPOSE: The objective of this study was to evaluate the safety and efficacy of immune checkpoint inhibitors in small cell lung cancer patients with brain metastases. METHODS: We retrospectively reviewed the records of small cell lung cancer patients with brain metastases treated with chemotherapy and radiotherapy for brain metastases with or without immune checkpoint inhibitors at our institution from January 2019 to January 2021. Patients were divided into two groups. In Group A, patients received chemotherapy and radiotherapy for brain metastases. In Group B, patients received chemotherapy, radiotherapy for brain metastases and at least four cycles of immunotherapy. Overall survival and intracranial progression-free survival were assessed using Kaplan-Meier estimates and Cox regression models. RESULTS: A total of 282 patients were enrolled in our study. At the end of the study (May 12, 2021), the median overall survival was 13.3 months among 218 patients in Group A and 33.4 months among 64 patients in Group B (hazards ratio [HR] 0.320, 95% confidence interval [CI], 0.189-0.545, P < 0.001). Both univariate and multivariate analyses suggested that two factors were significantly correlated with overall survival: the inclusion of immunotherapy in the regimen and the presence of extracranial metastases. The median intracranial progression-free survival was 6.93 months in Group A and 10.73 months in Group B (HR = 0.540, 95% CI, 0.346-0.841, P = 0.006). The intracranial objective response rate of Group B was greater than that of Group A, but the intracranial disease control rate was similar between the groups. CONCLUSION: Immunotherapy plus chemotherapy and radiotherapy for brain metastases showed promising efficacy for small cell lung cancer patients with brain metastases.
PURPOSE: The objective of this study was to evaluate the safety and efficacy of immune checkpoint inhibitors in small cell lung cancer patients with brain metastases. METHODS: We retrospectively reviewed the records of small cell lung cancer patients with brain metastases treated with chemotherapy and radiotherapy for brain metastases with or without immune checkpoint inhibitors at our institution from January 2019 to January 2021. Patients were divided into two groups. In Group A, patients received chemotherapy and radiotherapy for brain metastases. In Group B, patients received chemotherapy, radiotherapy for brain metastases and at least four cycles of immunotherapy. Overall survival and intracranial progression-free survival were assessed using Kaplan-Meier estimates and Cox regression models. RESULTS: A total of 282 patients were enrolled in our study. At the end of the study (May 12, 2021), the median overall survival was 13.3 months among 218 patients in Group A and 33.4 months among 64 patients in Group B (hazards ratio [HR] 0.320, 95% confidence interval [CI], 0.189-0.545, P < 0.001). Both univariate and multivariate analyses suggested that two factors were significantly correlated with overall survival: the inclusion of immunotherapy in the regimen and the presence of extracranial metastases. The median intracranial progression-free survival was 6.93 months in Group A and 10.73 months in Group B (HR = 0.540, 95% CI, 0.346-0.841, P = 0.006). The intracranial objective response rate of Group B was greater than that of Group A, but the intracranial disease control rate was similar between the groups. CONCLUSION: Immunotherapy plus chemotherapy and radiotherapy for brain metastases showed promising efficacy for small cell lung cancer patients with brain metastases.
Authors: Denise Bernhardt; Sebastian Adeberg; Farastuk Bozorgmehr; Nils Opfermann; Juliane Hörner-Rieber; Laila König; Jutta Kappes; Michael Thomas; Andreas Unterberg; Felix Herth; Claus Peter Heußel; Arne Warth; Jürgen Debus; Martin Steins; Stefan Rieken Journal: Strahlenther Onkol Date: 2017-10-30 Impact factor: 3.621
Authors: Vasileios Askoxylakis; Costas D Arvanitis; Christina S F Wong; Gino B Ferraro; Rakesh K Jain Journal: Adv Drug Deliv Rev Date: 2017-06-22 Impact factor: 15.470
Authors: Jonathan W Goldman; Mikhail Dvorkin; Yuanbin Chen; Niels Reinmuth; Katsuyuki Hotta; Dmytro Trukhin; Galina Statsenko; Maximilian J Hochmair; Mustafa Özgüroğlu; Jun Ho Ji; Marina Chiara Garassino; Oleksandr Voitko; Artem Poltoratskiy; Santiago Ponce; Francesco Verderame; Libor Havel; Igor Bondarenko; Andrzej Każarnowicz; György Losonczy; Nikolay V Conev; Jon Armstrong; Natalie Byrne; Piruntha Thiyagarajah; Haiyi Jiang; Luis Paz-Ares Journal: Lancet Oncol Date: 2020-12-04 Impact factor: 41.316
Authors: Anurag Gupta; Hans Christian Probst; Van Vuong; Alexandro Landshammer; Sabine Muth; Hideo Yagita; Reto Schwendener; Martin Pruschy; Alexander Knuth; Maries van den Broek Journal: J Immunol Date: 2012-06-08 Impact factor: 5.422
Authors: Denise Bernhardt; Laila König; Sophie Aufderstrasse; Johannes Krisam; Juliane Hoerner-Rieber; Sebastian Adeberg; Farastuk Bozorgmehr; Rami El Shafie; Kristin Lang; Jutta Kappes; Michael Thomas; Felix Herth; Claus Peter Heußel; Arne Warth; Samuel Marcrom; Jürgen Debus; Martin Steins; Stefan Rieken Journal: Clin Lung Cancer Date: 2017-12-15 Impact factor: 4.785
Authors: Shirish Gadgeel; Delvys Rodríguez-Abreu; Giovanna Speranza; Emilio Esteban; Enriqueta Felip; Manuel Dómine; Rina Hui; Maximilian J Hochmair; Philip Clingan; Steven F Powell; Susanna Yee-Shan Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Edward B Garon; Silvia Novello; Belén Rubio-Viqueira; Michael Boyer; Takayasu Kurata; Jhanelle E Gray; Jing Yang; Tuba Bas; M Catherine Pietanza; Marina C Garassino Journal: J Clin Oncol Date: 2020-03-09 Impact factor: 44.544
Authors: Daniel N Cagney; Allison M Martin; Paul J Catalano; Amanda J Redig; Nancy U Lin; Eudocia Q Lee; Patrick Y Wen; Ian F Dunn; Wenya Linda Bi; Stephanie E Weiss; Daphne A Haas-Kogan; Brian M Alexander; Ayal A Aizer Journal: Neuro Oncol Date: 2017-10-19 Impact factor: 12.300
Authors: Simon J Dovedi; Amy L Adlard; Grazyna Lipowska-Bhalla; Conor McKenna; Sherrie Jones; Eleanor J Cheadle; Ian J Stratford; Edmund Poon; Michelle Morrow; Ross Stewart; Hazel Jones; Robert W Wilkinson; Jamie Honeychurch; Tim M Illidge Journal: Cancer Res Date: 2014-10-01 Impact factor: 12.701